Scarica l'app Stockscreener
5.91
3.32%
0.19
Dopo l'orario di chiusura:
5.97
0.06
+1.02%
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting - MyChesCo
Block Trades: Is Verrica Pharmaceuticals Inc benefiting from innovation trendsM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Rallies: Is Verrica Pharmaceuticals Inc stock good for income investors2026 Decliners & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Big Picture: Will Verrica Pharmaceuticals Inc announce a stock split2026 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EPS Watch: Is Verrica Pharmaceuticals Inc stock a value trapWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Verrica Pharmaceuticals announces acceptance of late-breaking abstract highlighting potential abscopal effect of VP-315 for the treatment of basal cell carcinoma at the upcoming 2026 Society for Investigative Dermatology annual meeting - marketscreener.com
Skin cancer drug data from Verrica wins late-breaker slot in Chicago - Stock Titan
Chart Watch: Will Verrica Pharmaceuticals Inc announce a stock splitMarket Volume Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart.com
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Needham conference adds Verrica CEO; webcast runs live April 15 - Stock Titan
Published on: 2026-04-01 04:27:23 - baoquankhu1.vn
Market Trends: How does Verrica Pharmaceuticals Inc score in quality rankingsProfit Target & Safe Swing Trade Setups - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Growth in Short Interest - MarketBeat
Published on: 2026-03-31 18:08:06 - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart.com
Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN
Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - weeklyvoice.com
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - weeklyvoice.com
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe
FinancialContentVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - FinancialContent
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Verrica Pharmaceuticals schedules conference call to discuss 2025 results - MSN
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth - MyChesCo
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge - Investing.com Australia
YCANTH (VP-102): FDA-Approved Treatment for Molluscum Contagiosum and Dermatology Pipeline Overview | 2025 10-K Highlights - Minichart
VRCA: Revenue surged 368% in 2025, with strong YCANTH growth, cost cuts, and pipeline advances - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Verrica (VRCA) Achieves Strong Financial Milestones in 2025 - GuruFocus
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
[10-K] Verrica Pharmaceuticals Inc. Files Annual Report | VRCA SEC FilingForm 10-K - Stock Titan
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand - TradingView
VRCA: Revenue up 370% in 2025, net loss narrowed, debt repaid, and YCANTH sales nearly doubled - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold - MarketBeat
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results - MyChesCo
Earnings Outlook For Verrica Pharmaceuticals - Benzinga
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):